Revenue Comparison
Chart: Revenue Comparison. Values in USD billions. In Q2 2026: Pfizer 15.034, Viking Therapeutics 0.
Pfizer vs Viking Therapeutics Net Worth and Market Cap
Pfizer (PFE) and Viking Therapeutics (VKTX) are peers in GLP-1. Pfizer reported revenue of $15.0B as of Q2 2026, compared with $0 for Viking Therapeutics. Pfizer leads on revenue.
Key differences
- Pfizer's KPIs on Sterling include Abrysvo Revenues by Region (Quarterly) and Comirnaty Revenues by Region (Quarterly).
- Viking Therapeutics's KPIs on Sterling include Cash + Short-Term Investments (Quarterly) and Viking Oral VK2735 Phase 3 Timing.
Latest Quarter Comparison
Table: Latest Quarter Comparison. 15 rows across Metric, Pfizer, Viking Therapeutics.| Metric | Pfizer | Viking Therapeutics |
|---|---|---|
| Market Cap | - | - |
| Revenue | $15.03B | $0 |
| Cost of Revenue | $4.09B | $0 |
| Gross Profit | $10.94B | $0 |
| Operating Income | $4.71B | $-164.00M |
| Net Income | $-246.00M | $-158.00M |
| R&D Expense | $2.81B | $150.00M |
| Earnings Per Share | -$0.04 | -$1.37 |
| Gross Margin | 72.8% | - |
| Operating Margin | 31.3% | - |
| Net Profit Margin | -1.6% | - |
| Free Cash Flow | $302.00M | $-114.00M |
| Cumulative Free Cash Flow | $356.70B | $-747.00M |
| Operating Cash Flow | $835.00M | $-114.00M |
| Cash & Equivalents | $976.00M | $118.00M |